Talk:Oncofertility

From Embryology
Revision as of 10:32, 5 September 2015 by Z8600021 (talk | contribs) (Created page with "{{Talk Page}} ==2015== ===Fertility preservation in reproductive-age women facing gonadotoxic treatments=== Curr Oncol. 2015 Aug;22(4):e294-304. doi: 10.3747/co.22.2334. Rob...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
About Discussion Pages  
Mark Hill.jpg
On this website the Discussion Tab or "talk pages" for a topic has been used for several purposes:
  1. References - recent and historic that relates to the topic
  2. Additional topic information - currently prepared in draft format
  3. Links - to related webpages
  4. Topic page - an edit history as used on other Wiki sites
  5. Lecture/Practical - student feedback
  6. Student Projects - online project discussions.
Links: Pubmed Most Recent | Reference Tutorial | Journal Searches

Glossary Links

Glossary: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Numbers | Symbols | Term Link

Cite this page: Hill, M.A. (2024, June 17) Embryology Oncofertility. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/Talk:Oncofertility

2015

Fertility preservation in reproductive-age women facing gonadotoxic treatments

Curr Oncol. 2015 Aug;22(4):e294-304. doi: 10.3747/co.22.2334.

Roberts J1, Ronn R2, Tallon N1, Holzer H3.

Abstract

BACKGROUND: Advancements in the treatments for cancer and autoimmune and other hematologic conditions continue to improve survival and cure rates. Despite those changes, various gonadotoxic agents and other treatments can still compromise the future fertility of many women. Progress in medical and surgical reproductive technologies has helped to offset the reproductive consequences of the use of gonadotoxic therapies, and allows for future fertility and normal pregnancy. METHODS: A review of the literature was performed to outline the pathophysiology of gonadotoxicity from various treatments. The success of fertility preservation, fertility sparing, and cryopreservation options are reviewed. Barriers and facilitators to referral and oncofertility treatment in Canada are also outlined. RESULTS: According to the quality of the evidence, recommendations are made for fertility assessment, patient referral, cryopreservation, and other assisted reproductive technologies. CONCLUSIONS: To ensure ongoing fertility in women undergoing gonadotoxic treatments, assisted reproductive technologies can be combined with a multidisciplinary approach to patient assessment and referral. KEYWORDS: Oncofertility; adolescents; cryopreservation; fertility preservation; gonadotoxicity; young adults

PMID 26300680